Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 10 de 10
Filtrar
Mais filtros












Base de dados
Intervalo de ano de publicação
1.
Future Med Chem ; 16(10): 999-1027, 2024.
Artigo em Inglês | MEDLINE | ID: mdl-38910576

RESUMO

Aim: The objective of the present investigation was to design and synthesize new heterocyclic hybrids comprising benzothiazole and indenopyrazolone pharmacophoric units in a single molecular framework targeting α-amylase and α-glucosidase enzymatic inhibition. Materials & methods: 20 new benzothiazole-appended indenopyrazoles, 3a-t, were synthesized in good yields under environment-friendly conditions via cycloaddition reaction, and assessed for antidiabetic activity against α-amylase and α-glucosidase, using acarbose as the standard reference. Results: Among all the hydroxypyrazolones, 3p and 3r showed the best inhibition against α-amylase and α-glucosidase, which finds support from molecular docking and dynamic studies. Conclusion: Compounds 3p and 3r have been identified as promising antidiabetic agents against α-amylase and α-glucosidase and could be considered valuable leads for further optimization of antidiabetic agents.


[Box: see text].


Assuntos
Benzotiazóis , Inibidores de Glicosídeo Hidrolases , Hipoglicemiantes , Simulação de Acoplamento Molecular , alfa-Amilases , alfa-Glucosidases , alfa-Glucosidases/metabolismo , Benzotiazóis/química , Benzotiazóis/síntese química , Benzotiazóis/farmacologia , alfa-Amilases/antagonistas & inibidores , alfa-Amilases/metabolismo , Inibidores de Glicosídeo Hidrolases/síntese química , Inibidores de Glicosídeo Hidrolases/farmacologia , Inibidores de Glicosídeo Hidrolases/química , Hipoglicemiantes/química , Hipoglicemiantes/farmacologia , Hipoglicemiantes/síntese química , Humanos , Pirazóis/química , Pirazóis/farmacologia , Pirazóis/síntese química , Relação Estrutura-Atividade , Estrutura Molecular , Inibidores Enzimáticos/química , Inibidores Enzimáticos/farmacologia , Inibidores Enzimáticos/síntese química
2.
Luminescence ; 39(5): e4770, 2024 May.
Artigo em Inglês | MEDLINE | ID: mdl-38751216

RESUMO

The ultimate goal of nanoparticle-based phototherapy is to suppress tumor growth. Photothermal therapy (PTT) and photothermal photodynamic therapy (PDT) are two types of physicochemical therapy that use light radiation with multiple wavelength ranges in the near-infrared to treat cancer. When a laser is pointed at tissue, photons are taken in the intercellular and intracellular regions, converting photon energy to heat. It has attracted much interest and research in recent years. The advent of transition materials dichalcogenides (TMDCs) is a revolutionary step in PDT/PTT-based cancer therapy. The TMDCs is a multilayer 2D nano-composite. TMDCs contain three atomic layers in which two chalcogens squash in the transition metal. The chalcogen atoms are highly reactive, and the surface characteristics of TMDCs help them to target deep cancer cells. They absorb Near Infrared (NIR), which kills deep cancer cells. In this review, we have discussed the history and mechanism of PDT/PTT and the use of TMDCs and nanoparticle-based systems, which have been practiced for theranostics purposes. We have also discussed PDT/PTT combined with immunotherapy, in which the cancer cell apoptosis is done by activating the immune cells, such as CD8+.


Assuntos
Neoplasias , Fotoquimioterapia , Terapia Fototérmica , Elementos de Transição , Humanos , Neoplasias/tratamento farmacológico , Neoplasias/terapia , Neoplasias/patologia , Elementos de Transição/química , Elementos de Transição/farmacologia , Calcogênios/química , Calcogênios/farmacologia , Fármacos Fotossensibilizantes/química , Fármacos Fotossensibilizantes/farmacologia , Animais
3.
AAPS PharmSciTech ; 21(5): 164, 2020 Jun 02.
Artigo em Inglês | MEDLINE | ID: mdl-32488630

RESUMO

The aim of present research work was to design, fabricate, optimize, and evaluate allopurinol (ALLO)-loaded bovine serum albumin nanoparticles (ABNPs) for kidney targeting of the drug and exploring the potential of fabricated ABNPs for management of hyperuricemia-related nephrolithiasis. ABNP formulation was prepared by employing desolvation technique, and its optimization was conducted by 2-factor-3-level central composite design (CCD) in order to achieve minimum particle size (PSA) and polydispersity index (PDI), maximum entrapment efficiency (EE), and zeta potential (ZP). Further, the optimized formulation (ABNPsopt) was also assessed for in vitro drug release study, TEM, DSC, XRD analysis, FTIR spectroscopy, and in vivo animal study. The in vivo study revealed that after 2 h of ABNPsopt administration, a significant concentration of ALLO was present in kidney (21.26-fold) as compared with serum while in case of standard pure drug group; no drug was seen in mice kidney and serum post 2 h administration, which indicates successful targeting of ALLO by formulating its albumin nanoparticles. Also, uric acid and pH levels were measured in serum and urine samples of mice which showed significant (P < 0.01) efficacy of ABNPsopt formulation in management of hyperuricemia-related nephrolithiasis. Histological studies on kidney samples also confirmed these outcomes. Findings of present study indicate higher kidney uptake of allopurinol from formulated ABNPsopt, which could be due to the specificity of albumin polymer for cubilin and megalin receptors, and it also serves as effective strategy in management of hyperuricemic-related nephrolithiasis.


Assuntos
Alopurinol/administração & dosagem , Supressores da Gota/administração & dosagem , Hiperuricemia/tratamento farmacológico , Nefrolitíase/tratamento farmacológico , Soroalbumina Bovina/química , Alopurinol/uso terapêutico , Animais , Portadores de Fármacos/química , Composição de Medicamentos , Supressores da Gota/uso terapêutico , Humanos , Hiperuricemia/complicações , Rim , Camundongos , Nanopartículas/química , Nefrolitíase/complicações , Tamanho da Partícula
4.
Daru ; 27(2): 661-671, 2019 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-31686374

RESUMO

PURPOSE: The major short coming of conventional therapy system is that they can't deliver the therapeutics specifically to a site within the body without producing nonspecific toxicity. Present research aimed at developing kidney targeted allopurinol (AP) loaded chitosan coated magnetic nanoparticles (A-MNPs) for the management of hyperuricemic nephropathy manifested in the form of nephrolithiasis. METHODS: The work includes preparation of magnetic nanoparticles by chemical co-precipitation method and evaluation of the prepared batches for particle size analysis, Transmission electron microscopy, entrapment efficiency, in-vitro release study etc. Further, FTIR spectroscopy, X-ray diffraction, Differential Scanning Calorimetry, Vibrational sample magnetometer (VSM) and in-vivo animal studies were also performed. RESULTS: VSM analysis demonstrates that the prepared nanoparticles exhibit superparamagnetic magnetic behaviour which was retained even after coating by chitosan. In-vivo studies of A-MNPs showed 19.07-fold increase in kidney uptake of AP as compared to serum post 2 h of administration in mice whereas no drug was detected in kidney and serum post 2 h administration of pure drug (free-form) indicating successful targeting to kidney as well as sustained release of AP from the formulated A-MNPs. The significant (p < 0.01) effectiveness of A-MNPs in management of hyperuricemic nephrolithiasis was observed through estimating pH and uric acid levels in urine and serum samples of mice. These findings were also confirmed by histological examination of isolated kidney samples. CONCLUSION: Present investigation signifies that a simple external magnetic field is enough for targeting allopurinol to kidneys by formulating A-MNPs which further offers an effective approach for management of hyperuricemic nephrolithiasis. Graphical Abstract.


Assuntos
Alopurinol/administração & dosagem , Quitosana/química , Rim/química , Nefrolitíase/tratamento farmacológico , Administração Oral , Alopurinol/química , Alopurinol/farmacocinética , Animais , Precipitação Química , Modelos Animais de Doenças , Sistemas de Liberação de Medicamentos , Nanopartículas de Magnetita , Camundongos , Nanopartículas , Nefrolitíase/sangue , Nefrolitíase/induzido quimicamente , Nefrolitíase/urina , Ácido Oxônico/efeitos adversos , Ácido Úrico/sangue , Ácido Úrico/urina
5.
Inflammopharmacology ; 27(2): 301-311, 2019 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-29464495

RESUMO

Essential oil of eucalyptus species is among the most common traded essential oils in the world. There is an increasing interest in the application of eucalyptus oil as a natural additive in food and pharmaceutical industry. The present study was undertaken to identify the phytoconstituents present in the essential oil of Eucalyptus globulus leaves (EO) and ascertain their protective effect against ketamine-induced psychosis in rats. GC-MS technique was used for analysis of phytoconstituents present in EO. Ketamine (50 mg/kg, i.p.) was used to induce psychosis in rats. Photoactometer, forced swim test and pole climb avoidance test were used to evaluate the protective effects of the EO (500, 1000 and 2000 mg/kg, p.o.) on acute and chronic administration. Bar test was used to test the side effect of EO. Biochemical and neurochemical estimations were carried out to explore the possible mechanism of action. GC-MS analysis of EO showed the presence of a number of biologically active compounds. EO at the dose of 500, 1000 and 2000 mg/kg, p.o. on acute and chronic administration, decreased locomotor activity, immobility duration and latency to climb the pole. EO was effective to facilitate the release of GABA, increase GSH levels, inhibit dopamine neurotransmission and decrease TNF-α levels as well as diminish AChE activity in different regions of the brain. EO at the dose of 500, 1000 mg/kg did not produce cataleptic behavior in rats. EO at the dose of 500, 1000 mg/kg produced protective effects against ketamine-induced psychosis and can be further explored clinically against neuropsychiatric disorders.


Assuntos
Acetilcolinesterase/metabolismo , Citocinas/metabolismo , Dopamina/metabolismo , Óleo de Eucalipto/farmacologia , Eucalyptus/química , Estresse Oxidativo/efeitos dos fármacos , Transtornos Psicóticos/tratamento farmacológico , Ácido gama-Aminobutírico/metabolismo , Animais , Ketamina/farmacologia , Masculino , Óleos Voláteis/farmacologia , Transtornos Psicóticos/metabolismo , Ratos , Ratos Wistar , Fator de Necrose Tumoral alfa/metabolismo
6.
Biomed Pharmacother ; 105: 1015-1025, 2018 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-30021336

RESUMO

Schizophrenia is one of the psychotic mental disorders characterized by symptoms of thought, behavior, and social problems. Newer biomedicine and pharmacotherapy has been investigated for the treatment of various neuropsychiatric disorders in the past few decades. Spinacia oleracea is one of these, reported to have beneficial effect against several neurodegenerative disorders. The present study was carried to explore the protective effects of Spinacia oleracea seed extract (SOEE) in an experimental model of ketamine-induced schizophrenia in mice. Ketamine (50 mg/kg, i.p.) was used to induce stereotyped psychotic behavioural symptoms in mice. Behavioral studies (locomotor activity, stereotype behaviors, immobility duration and memory retention) were carried out to investigate the protective of SOEE on ketamine-induced psychotic symptoms, followed by biochemical, neurochemical and cellular alterations in the brain. Treatment with SOEE for 15 consecutive days significantly attenuated stereotyped behavioral symptoms in mice. Biochemical estimations revealed that SOEE reduced lipid peroxidation and restored total brain proteins. Furthermore, SOEE remarkably reduced dopamine levels, AChE activity & inflammatory surge (serum TNF-α) and increased the levels of GABA and reduced glutathione in mice. The outcomes of the study suggested that SOEE could ameliorate ketamine-induced psychotic symptoms in mice, indicating a protective effect in the treatment of schizophrenia.


Assuntos
Química Encefálica/efeitos dos fármacos , Modelos Animais de Doenças , Fármacos Neuroprotetores/uso terapêutico , Extratos Vegetais/uso terapêutico , Esquizofrenia/tratamento farmacológico , Spinacia oleracea , Anestésicos Dissociativos/toxicidade , Animais , Antipsicóticos/isolamento & purificação , Antipsicóticos/farmacologia , Antipsicóticos/uso terapêutico , Aprendizagem da Esquiva/efeitos dos fármacos , Aprendizagem da Esquiva/fisiologia , Química Encefálica/fisiologia , Feminino , Ketamina/toxicidade , Masculino , Camundongos , Fármacos Neuroprotetores/isolamento & purificação , Fármacos Neuroprotetores/farmacologia , Extratos Vegetais/isolamento & purificação , Extratos Vegetais/farmacologia , Esquizofrenia/induzido quimicamente , Esquizofrenia/metabolismo , Sementes
7.
Pharmacol Rep ; 70(3): 591-599, 2018 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-29679883

RESUMO

BACKGROUND: Stigmasterol, a naturally occurring phytoestrogen has been reported to possess many pharmacological activities. The aim of the present study was to screen the effect of stigmasterol against ketamine-induced mice model of psychosis. METHODS: The behavioural studies included an assessment of locomotor activity, stereotypic behaviours, immobility duration, step down latency and effects on catalepsy. Biochemical estimations involved the estimations of GABA, dopamine, GSH, MDA, TNF-α, total protein content and AChE activity. Histopathological changes and effect on androgenic parameters were also evaluated. RESULTS: Stigmasterol treated animals showed significant decrease in locomotor activity, stereotypic behaviours, immobility duration and increased step down latency. Biochemical estimations revealed increased GABA, GSH levels and decreased dopamine, MDA, TNF-α levels and AChE activity. These findings were confirmed by histopathological changes in the cortex part of the brain. Further, stigmasterol was not found to cause catalepsy and any adverse effect on the reproductive system. CONCLUSION: This study concluded that stigmasterol could ameliorate ketamine-induced behavioral, biochemical and histopathological alterations in mice showing its potential effects in the management of psychotic symptoms.


Assuntos
Antipsicóticos/farmacologia , Substâncias Protetoras/farmacologia , Transtornos Psicóticos/tratamento farmacológico , Estigmasterol/farmacologia , Acetilcolina/metabolismo , Animais , Encéfalo/efeitos dos fármacos , Encéfalo/metabolismo , Catalepsia/tratamento farmacológico , Catalepsia/metabolismo , Modelos Animais de Doenças , Dopamina/metabolismo , Glutationa/metabolismo , Ketamina/farmacologia , Masculino , Malondialdeído/metabolismo , Camundongos , Atividade Motora/efeitos dos fármacos , Estresse Oxidativo/efeitos dos fármacos , Transtornos Psicóticos/metabolismo , Fator de Necrose Tumoral alfa/metabolismo , Ácido gama-Aminobutírico/metabolismo
8.
Biomed Pharmacother ; 98: 207-213, 2018 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-29268241

RESUMO

Ketamine, N-methyl-d-aspartate receptor antagonist has been implanted in such behavioural and biochemical alterations in animals similar to human psychosis. Spermidine, a biogenic polyamine, involved in various cellular functions in living organisms, on the contrary possess NMDA receptor agonistic effect. Therefore, we aimed to study the effect of spermidine (10 and 20 mg/kg, i.p.) in ketamine (50 mg/kg, i.p.) induced psychotic symptoms using various behavioural animal models. Biochemical assays were done to confirm the molecular pathways associated with spermidine and psychosis. Spermidine was significant to alleviate the ketamine-induced psychotic symptoms as indicated by decrease in locomotor activity in actophotometer, stereotypic behaviours, immobility duration in force swim test and latency to climb the pole in pole climb avoidance test. Interestingly, spermidine significantly decreased acetylcholinesterase (AChE) activity, serum tumor necrosis factor (TNF-α), dopamine and malondialdehyde (MDA) level while increased gamma-amino butyric acid and reduced glutathione (GSH) level in different regions of brain. Spermidine did not produce cataleptic effect on bar test at lower dose, but at the higher dose its cataleptic effect was similar to haloperidol. Based on behavioural and biochemical results, present study revealed spermidine as a promising antipsychotic biomolecule, however, its cataleptic effect at higher doses must be ruled out before use in clinical settings.


Assuntos
Acetilcolinesterase/metabolismo , Citocinas/metabolismo , Dopamina/metabolismo , Estresse Oxidativo/fisiologia , Transtornos Psicóticos/metabolismo , Espermidina/uso terapêutico , Ácido gama-Aminobutírico/metabolismo , Animais , Antipsicóticos/farmacologia , Antipsicóticos/uso terapêutico , Encéfalo/efeitos dos fármacos , Encéfalo/metabolismo , Citocinas/antagonistas & inibidores , Feminino , Mediadores da Inflamação/antagonistas & inibidores , Mediadores da Inflamação/metabolismo , Ketamina/toxicidade , Masculino , Estresse Oxidativo/efeitos dos fármacos , Transtornos Psicóticos/tratamento farmacológico , Ratos , Ratos Wistar , Espermidina/farmacologia , Resultado do Tratamento
9.
Inflammopharmacology ; 26(2): 413-424, 2018 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-28577133

RESUMO

Gallic acid has been reported to possess a number of psychopharmacological activities. These activities are attributed to the antioxidant potential due to the presence of phenolic moeity. The present study was carried out to investigate the protective effects of gallic acid in an experimental model of ketamine-induced psychosis in mice. Ketamine (50 mg/kg, i.p.) was used to induce stereotyped psychotic behavioural symptoms in mice. Behavioural studies (locomotor activity, stereotype behaviour, immobility duration and memory retention) were carried out to investigate the protective of gallic acid on ketamine-induced psychotic symptoms, followed by biochemical and neurochemical changes and cellular alterations in the brain. Chronic treatment with gallic acid for 15 consecutive days significantly attenuated stereotyped behavioural symptoms in mice. Biochemical estimations revealed that gallic acid reduced the lipid peroxidation and restored the total brain proteins. Furthermore, gallic acid remarkably reduced the dopamine levels, AChE activity and inflammatory surge (serum TNF-α), and increased the levels of GABA and increased glutathione in mice. The study revealed that gallic acid could ameliorate psychotic symptoms and biochemical changes in mice, indicating protective effects in psychosis.


Assuntos
Ácido Gálico/farmacologia , Ketamina/farmacologia , Substâncias Protetoras/farmacologia , Transtornos Psicóticos/tratamento farmacológico , Animais , Antioxidantes/metabolismo , Comportamento Animal/efeitos dos fármacos , Encéfalo/efeitos dos fármacos , Encéfalo/metabolismo , Modelos Animais de Doenças , Feminino , Glutationa/metabolismo , Peroxidação de Lipídeos/efeitos dos fármacos , Masculino , Camundongos , Atividade Motora/efeitos dos fármacos , Transtornos Psicóticos/metabolismo , Fator de Necrose Tumoral alfa/metabolismo , Ácido gama-Aminobutírico/metabolismo
10.
Drug Deliv ; 24(1): 1429-1440, 2017 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-28942680

RESUMO

To develop statistically optimized brain targeted Tween 80 coated chitosan nanoparticulate formulation for oral delivery of doxycycline hydrochloride for the treatment of psychosis and to evaluate its protective effect on ketamine induced behavioral, biochemical, neurochemical and histological alterations in mice. 32 full factorial design was used to optimize the nanoparticulate formulation to minimize particle size and maximize entrapment efficiency, while independent variables chosen were concentration of chitosan and Tween 80. The optimized formulation was characterized by particle size, drug entrapment efficiency, Fourier transform infrared, Transmission electron microscopy analysis and drug release behavior. Pure doxycycline hydrochloride (25 and 50 mg/kg, p.o.) and optimized doxycycline hydrochloride encapsulated Tween 80 coated chitosan nanoparticles (DCNPopt) (equivalent to 25 mg/kg doxycycline hydrochloride, p.o.) were explored against ketamine induced psychosis in mice. The experimental studies for DCNPopt, with mean particle size 237 nm and entrapment efficiency 78.16%, elucidated that the formulation successfully passed through blood brain barrier and exhibited significant antipsychotic activity. The underlying mechanism of action was further confirmed by behavioral, biochemical, neurochemical estimations and histopathological study. Significantly enhanced GABA and GSH level and diminished MDA, TNF-α and dopamine levels were observed after administration of DCNPopt at just half the dose of pure doxycycline hydrochloride, showing better penetration of doxycyline hydrochloride in the form of Tween 80 coated nanoparticles through blood brain barrier. This study demonstrates the hydrophilic drug doxycycline hydrochloride, loaded in Tween 80 coated chitosan nanoparticles, can be effectively brain targeted through oral delivery and therefore represents a suitable approach for the treatment of psychotic symptoms.


Assuntos
Encéfalo , Nanopartículas , Transtornos Psicóticos , Animais , Quitosana , Doxiciclina , Portadores de Fármacos , Ketamina , Camundongos , Tamanho da Partícula , Polissorbatos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...